CD274 and neoplasm: The primary endpoint was OS for durvalumab monotherapy vs. EXTREME in PD-L1 high expressers (tumor cell expression of >50% or tumor-infiltrating lymphocyte expression >25%) and secondary endpoint of OS for durvalumab plus tremelimumab vs. EXTREME for all patients.